Results 221 to 230 of about 516,619 (288)

Engineered bispecific antibodies achieve broad and potent protection against multiple ebolavirus species. [PDF]

Emerg Microbes Infect
Zhou J, Zhang B, Yao Y, Li F, Chen S, Wu Y, Xie Y, Guo X, Li W, Peng C, Peng Y, Gao G, Yan F, Gong R, Zhang X, Chiu S.   +15 more
europepmc   +1 more source

CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis. [PDF]

Front Oncol
Li MJ, Qiu L, Chen D, Li CY, He Y, Li YL, Cen YL, Ren SH, Yao H, Fan FY.   +9 more
europepmc   +1 more source

Infections after bispecific antibodies in B-cell lymphomas. [PDF]

Blood Adv
Kim DH, Lee N, Koh Y, Jo HJ, Kang CK, Choe PG, Park WB, Lee CM, Byun JM, Kim NJ.   +9 more
europepmc   +1 more source

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz, Martin Ebinger, Michaela Döring, Markus Mezger, Ursula Holzer, Rupert Handgretinger, Peter Lang, Manon Queudeville   +7 more
wiley   +1 more source

The LVI Component Hypothesis: the lymphatic-to-vascular invasion ratio as an enrichment biomarker for therapy with PD-L1×VEGF-A bispecific antibodies. [PDF]

Front Immunol
Kern KA.
europepmc   +1 more source

From Molecular Targets to Advanced Delivery Systems: Aptamers for Precision Ocular Therapeutics

Advanced Therapeutics, Volume 9, Issue 10, October 2026.
Aptamer‐based strategies are revolutionizing ocular disease management through highly specific molecular recognition of disease specific molecular targets. This review systematically integrates therapeutic aptamer sequences, diagnostic aptasensor platforms, and targeted delivery strategies, highlighting design principles, ocular bioavailability ...
Minal Thacker, Ka‐Ying Wong, Liping Zhou, Man‐Sau Wong, Juewen Liu   +4 more
wiley   +1 more source

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review. [PDF]

Ann Hematol
Benda M, Reimann P, Willenbacher W, Gunsilius E, Weisel K, Strassl I, Krauth MT, Knop S, Winder T, Steiner N.   +9 more
europepmc   +1 more source

Target-Specific Dermatological Adverse Event Reporting With T-Cell-Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of FAERS and Canada Vigilance, 2016-2026. [PDF]

Cancer Med
Mandal S, Maji M, Dhali A.
europepmc   +1 more source

Early Integration of CAR T‐Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors

Hematological Oncology, Volume 44, Issue 6, November 2026.
Carlo Visco, Stefania Bramanti, Paolo Corradini, Enrico Derenzini, Pier Luigi Zinzani   +4 more
wiley   +1 more source

Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy. [PDF]

Mol Cancer
Battistini E, Lapuhs P, Jiménez A, Garrido-Areal S, Rivas-Gómez L, Zagorac I, Álvarez-Vallina L, Alonso MJ, Sanjurjo L.   +8 more
europepmc   +1 more source